TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An update from Adagene ( (ADAG) ) is now available.
On November 13, 2025, Adagene Inc. announced a licensing agreement with Third Arc Bio, allowing the latter to use Adagene’s SAFEbody technology to develop two masked CD3 T cell engagers. This agreement grants Third Arc Bio worldwide rights to research, develop, and commercialize these molecules, while Adagene receives an upfront payment of $5 million and potential milestone payments up to $840 million. The collaboration is expected to enhance Adagene’s industry positioning by expanding the application of its SAFEbody technology, potentially leading to innovative cancer therapies with improved safety profiles.
The most recent analyst rating on (ADAG) stock is a Sell with a $1.50 price target. To see the full list of analyst forecasts on Adagene stock, see the ADAG Stock Forecast page.
Spark’s Take on ADAG Stock
According to Spark, TipRanks’ AI Analyst, ADAG is a Underperform.
Adagene’s overall stock score is primarily impacted by its poor financial performance, characterized by declining revenues and significant losses. Technical analysis indicates a bearish trend, and valuation metrics highlight concerns with a negative P/E ratio. The absence of earnings call data and corporate events limits additional insights.
To see Spark’s full report on ADAG stock, click here.
More about Adagene
Adagene Inc. is a clinical-stage biotechnology company focused on developing novel antibody-based cancer immunotherapies. Utilizing its proprietary Dynamic Precision Library platform, Adagene combines computational biology and artificial intelligence to design antibodies that address unmet global patient needs. The company’s SAFEbody technology is designed to improve the safety and efficacy of antibody therapeutics by enabling tumor-specific targeting, minimizing off-target effects.
Average Trading Volume: 97,784
Technical Sentiment Signal: Strong Sell
Current Market Cap: $83.42M
For detailed information about ADAG stock, go to TipRanks’ Stock Analysis page.